RESUMEN
Objective To evaluate the clinical efficacy of mesalazine sustained-release tablets in combination with azathioprine in the small intestine Crohn’s disease therapy.Methods 60 cases of small intestinal Crohn disease patients were randomly divided into two groups and the control group 30 cases.Observation group mesalazine sustained-release tablets 1.5 mg ~2.0 mg/( kg? d ) , 1 ~2 times/d, the other in combination with azathioprine 1 g/times, 2 times/d treatment;control group received azathioprine alone 1 g/times, 2 times/d, both groups were treated for 30 weeks after treatment were compared activity index score, clinical remission rate, mucosal healing rate, blood biochemical parameters before and after treatment, and record adverse reactions during treatment.ResuIts The two groups of patients after treatment than before treatment activity index score decreased significantly (P<0.05), but the observation group were more than the control group decreased significantly (P<0.05); observation group complete remission rate and mucosal healing rates better than the control group (P<0.05);the WBC count, ESR and CRP level were lower than before treatment (P<0.05);AIL two levels and TLB levels were significantly increased compared with that before treatment (P<0.01), but the observation group was significantly higher than that in the control group ( P<0.05 ); the incidence of adverse observation group were 26.67%, significantly higher than the 6.67%( P<0.05 ) .ConcIusion Mesalazine sustained-release tablets in combination with azathioprine therapy compared with small bowel Crohn’s disease treatment is more effective azathioprine alone, can significantly improve the therapeutic effect, but incidence of adverse reactions is higher.